How to treat adverse reactions caused by Platinib?

Introduction: Platinib is a once-daily oral RET-targeted therapy designed to selectively and effectively inhibit RET mutations that cause multiple cancer types, including approximately 1%-2% of NSCLC patients. Platinib is currently used to treat adult patients with metastatic RET fusion-positive non-small cell lung cancer.

Adverse reactions of platinib

1. Gastrointestinal diseases: constipation, diarrhea, nausea, dry mouth.

2. Musculoskeletal and connective tissue diseases: myalgia, joint pain, limb pain, neck pain, musculoskeletal pain, back pain, elevated blood creatine phosphokinase.

3. Respiratory, chest and mediastinal diseases: cough, upper respiratory tract cough syndrome, shortness of breath.

4. Skin and subcutaneous tissue diseases: rash, maculopapular rash, acneiform dermatitis, erythema, generalized rash, papule, macular rash, erythematous rash.

Measures to deal with the adverse reactions of Platinib

1. Hypertension: may cause high blood pressure. Patients need to monitor their blood pressure regularly and use antihypertensive drugs for management when necessary.

2. Liver toxicity: Liver function should be checked before treatment and monitored regularly during treatment. If AST/ALT increases, medication may need to be suspended and the dosage or treatment plan adjusted under the guidance of a physician.

3. Myelosuppression: Platinib may cause neutropenia and anemia. Patients should undergo regular blood routine examinations and adjust treatment plans if necessary.

4. Digestive system reactions: Digestive system reactions such as nausea, vomiting and diarrhea are relatively common. Patients can relieve symptoms by adjusting their diet, using anti-nausea drugs or rehydration.

5. Skin reaction: Skin problems such as rashes may occur. Patients should keep their skin clean and moist, and seek medical help if necessary.

6. Hyperphosphatemia and hypocalcemia: Platinib treatment may cause electrolyte abnormalities, and blood phosphorus and blood calcium levels need to be monitored and corresponding measures taken if necessary.

Clinical efficacy of platinib

A major study showed , which effectively reduced tumor size in patients with RET fusion-positive NSCLC who had not previously received treatment or who had received platinum-based chemotherapy. In this study, platinib was not compared with any other treatment or placebo.

Treatment response is assessed through body scans, with a complete response meaning the patient has no more signs of cancer. Among treatment-naïve patients, approximately 72% had a complete or partial response to platinib treatment. About 59% of patients who received platinib after platinum-based chemotherapy had a complete or partial response to platinib treatment.